Previous close | 60.28 |
Open | 60.73 |
Bid | 60.02 x 50000 |
Ask | 60.07 x 50000 |
Day's range | 59.85 - 60.98 |
52-week range | 59.85 - 80.08 |
Volume | |
Avg. volume | 507 |
Market cap | 75.286B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | 176.68 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (4.78%) |
Ex-dividend date | 14 Jun 2024 |
1y target est | N/A |
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.